Ernexa Therapeutics Inc. — Director's Dealing 2021

Mar 26, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Brooklyn ImmunoTherapeutics, Inc. (BTX)
CIK: 0000748592
Period of Report: 2021-03-24

Reporting Person: Wolff Allen (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-24	Common Stock	F	9944	$2.67	Disposed	128520	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	2100	Indirect
Common Stock	2100	Indirect

Footnotes

F1: These shares were withheld by the issuer to satisfy statutory tax withholding requirements on vesting of restricted stock units that occurred in connection with the closing of the merger (the "Merger") contemplated by the Agreement and Plan of Merger and Reorganization (the "Merger Agreement") by and among NTN Buzztime Inc., BIT Merger Sub, Inc. and Brooklyn Immunotherapeutics LLC. The number of shares withheld was determinable on March 24, 2021. No shares were sold in connection with this transaction. None of the share amounts in this Form 4 reflect the 2 for 1 reverse stock split implemented by the issuer on March 25, 2021 in connection with the Merger.

F2: As custodian of Child 1.

F3: As custodian of Child 2.